The rest of the 100 (in alphabetical order by company): Fay Xing, Wuxi Ventures
Fay Xing is a partner at WuXi Healthcare Ventures (WHV). The firm is the corporate venturing unit for China-based pharmaceutical research company WuXi PharmaTech and which merged in May with Frontline BioVentures to form 6 Dimensions Capital and subsequently raised a $533m fund and a RMB2.06bn ($316m) Chinese currency one in December.
A medical professional by training, Xing spent four years training at Stanford from 2000 to 2004. While there she set up CardioCool, running that until 2005. After a residential stint at New York Presbyterian, she moved into the business side of the healthcare industry at Medtronic via a Harvard MBA.
2010 saw Xing leave Medtronic, and become principal at Dencheng Capital/Bay City Capital, based in Shanghai. She also became a Kauffman Fellow, the venture capital leadership education program.
From 2015, Xing has been based in both Shanghai and San Francisco in her current role as partner for WHV. Last year saw WHV, which retains its website as does Frontline, rather than a combined new entity site, make six deals, leading the only series A round they took part in, but otherwise preferring to join series B rounds.
In February last year, WHV took part in Forerunner Medical’s series B round for an undisclosed amount. Forerunner develops innovative medical techniques, with an emphasis on non-invasive procedures.
WHV joined F-Prime Capital Partners to help raise $10m for medical technology infusion management developer Ivenix’s funding round in March.
In June, Vivace Therapeutics raised $25m in their series B round, a round that saw WHV join Sequoia Capital among others to back the developer for novel pathways to combat cancer.
In the only round that WHV led all year, they and seven other firms raised $55m in the series A round for LifeMine Therapeutics, a DNA-led biotechnology drug discovery company.
September saw WHV take part in XW Laboratories’ B round, worth an eventual $17.5m to the biopharmaceutical company focused on developing drugs to combat neurological disorders.
WHV was a part of Medeor Therapeutics’ B round in November, as the personalised cellular therapy developer raised $57m and then led AnchorDX’s series B round that wound up at $28m in November.